Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GSK 732462 HIV Vaccine in ART-naïve Patients
NCT01218113Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2010
- Primary completion
- Nov 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of GSK 732462 in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by GSK. Primary endpoints: Geometric Mean Change in HIV-1 Viral Load From Baseline at Week 48, Number of Subjects With Solicited Local Symptoms and 4 more. Started Nov 2010; status: completed.
02
Drugs
GSK 732462
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01218113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218113.